Are GLP-1 receptor agonists associated with an increased risk of suicidal ideation/ behavior?

This article was first published on February 2, 2024. It was last reviewed, updated, or edited on February 3, 2024. Glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound™), among others, are an exciting advance in the treatment of obesity/overweight and diabetes mellitus. But are GLP-1 receptor agonists associated with an…